Trading in Isofol’s shares commences today on Nasdaq Stockholm
GOTHENBURG, Sweden, October 21, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that […]
Other Corporate Information
Isofol Medical AB (publ) intends to list its shares on Nasdaq Stockholm
GOTHENBURG, Sweden, October 15, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the
Company presentation at LSX Nordic Congress 2021
From September 7-17 Isofol participated in LSX Nordic Congress, an opportunity for 1:1 meetings with Nordic life science executives focused
Isofol completes recruitment of Japanese patients in the global phase III AGENT study
GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market:
Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announced on
Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients
GOTHENBURG, Sweden, March 19, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study
GOTHENBURG, Sweden, January 15, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Isofol reaches 440 patients in global Phase III AGENT study
GOTHENBURG, Sweden, December 9, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada
GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today